Prevention of biofilm formation in dialysis water treatment systems

被引:36
作者
Smeets, E
Kooman, J
van der Sande, F
Stobberingh, E
Frederik, P
Claessens, P
Grave, W
Schot, A
Leunissen, K
机构
[1] Univ Hosp Maastricht, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands
[2] Univ Hosp Maastricht, Dept Med Microbiol, NL-6202 AZ Maastricht, Netherlands
[3] St Laurentius Hosp Roermond, Dept Internal Med, Roermond, Netherlands
[4] Univ Maastricht, Dept Electron Microscopy, Maastricht, Netherlands
关键词
biofilm water treatment system; hemodialysis;
D O I
10.1046/j.1523-1755.2003.00888.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Biofilm formations in dialysis systems may be relevant because they continuously release bacterial compounds and are resistant against disinfection. The aim of the study was to compare the development of biofilm between a water treatment system based on a single reverse osmosis unit producing purified dialysate water [bacterial count, 350 colony-forming unit (CFU)/L] (center A) and a water treatment system based on double reverse osmosis and electric deionization, which is continuously disinfected with ultraviolet light and treated with ozone once a week (bacterial count, 1 CFU/L) (center B). Methods. During a period of 12 weeks, biofilm formation was studied in the tubing segment between the water piping and the dialysis module, using four dialysis monitors in each center. On a weekly basis, tubing samples of 5 cm length (N = 96) were taken under aseptic conditions and investigated for microbiologic contamination [cystine lactose electrolyte-deficient (CLED) Agar], endotoxin levels [limulus amoeben lysate (LAL) gel test, cutoff value, 0.0125 EU/mL], and biofilm formation [electron scanning microscopy (SEM)]. Results. In center A, tube cultures were positive (>100 CFU/mL) in 16% of samples at 22degreesC and 37degreesC, compared to 3% of samples of center B (P < 0.05; chi-square). Endotoxin levels were positive in 76% of the tubing samples of center A and negative in all of the samples of center B (P < 0.05). Biofilm was present in 91.7% of the samples of center A (Fig. 1), and only present in one sample (taken after 9 weeks) of center B (P < 0.05) (Fig. 2). In center A, biofilm formation was already observed after 1 week. Conclusion. In contrast to a standard water treatment system producing purified water, the use of a system producing highly purified water, which is also treated with regular disinfection procedures, leads to a significant reduction in biofilm formation, bacterial growth, and endotoxin levels in a highly vulnerable part of a water treatment system.
引用
收藏
页码:1574 / 1576
页数:3
相关论文
共 8 条
[1]   Microbiologic purity of dialysate: Rationale and technical aspects [J].
Canaud, B ;
Bosc, JY ;
Leray, H ;
Morena, M ;
Stec, F .
BLOOD PURIFICATION, 2000, 18 (03) :200-213
[2]   Microbiological purity of dialysate for on-line substitution fluid preparation [J].
Canaud, B ;
Bosc, JY ;
Leray, H ;
Stec, F .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 :21-30
[3]   Biofilms invade nephrology: Effects in hemodialysis [J].
Cappelli, G ;
Ballestri, M ;
Perrone, S ;
Ciuffreda, A ;
Inguaggiato, P ;
Albertazzi, A .
BLOOD PURIFICATION, 2000, 18 (03) :224-230
[4]   The quality of dialysate: An integrated approach [J].
Lonnemann, GR .
KIDNEY INTERNATIONAL, 2000, 58 :S112-S119
[5]   Evidence of bacterial biofilm in tubing from hydraulic pathway of hemodialysis system [J].
Man, NK ;
Degremont, A ;
Darbord, JC ;
Collet, M ;
Vaillant, P .
ARTIFICIAL ORGANS, 1998, 22 (07) :596-600
[6]   Does ultrapure dialysate prevent the development of biofilm in dialysis therapy? [J].
Penders, C ;
Kooman, JP ;
Stobberingh, EE ;
van der Sande, FM ;
Frederik, PM ;
Leunissen, KML .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (07) :1522-1524
[7]   Microbial biofilm formation and contamination of dental-unit water systems in general dental practice [J].
Walker, JT ;
Bradshaw, DJ ;
Bennett, AM ;
Fulford, MR ;
Martin, MV ;
Marsh, PD .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2000, 66 (08) :3363-3367
[8]  
2002, PHARMEUROPA, V14, P70